Sammie is a highly regarded member of the inheritable bleeding disorders community and a lived experience expert. Diagnosed with von Willebrand disease (VWD) at the age of 32, she navigates her personal journey with remarkable resilience. Beyond…
Sundar Selvaraj is a research specialist at the University of Michigan, Ann Arbor, MI, focusing on biomedical research on factor VIII and hemophilia A. Diagnosed with an ultra rare combination of severe factor XIII deficiency and type 2 M von…
Raymond “Ray” Stanhope LEE (Lived Experience Expert), President of the Lone Star Bleeding Disorders Foundation and Co-Chair LEE WG for the National Research Blueprint (NRB), he is a person living with severe hemophilia B. For over 30 years, he has…
Dr. Singleton, speaking on behalf of HEMA Biologics, will discuss a treatment option for patients 12 years of age or older with hemophilia A or B with inhibitors. Sponsored by HEMA Biologics.Speakers: Tammuella “Tami” Chrisentery-…
Sanofi invites you to join an educational symposium where Dr. Jain will introduce a new rebalancing subcutaneous injection treatment for hemophilia A and B. This presentation will cover the benefits and safety of this new treatment, as well as how…
Pathway to Cures’ investment in Spark Biomedical is an example of how we foster the development of innovative approaches to healthcare access and unmet medical needs in the blood and bleeding disorders community.Spark Biomedical’s hemostasis…
This session explores the latest advances and challenges in research focused on children and adolescents with inherited bleeding disorders, such as hemophilia, von Willebrand disease, and other rare conditions. Our expert speakers will…
Roche (and Roche group member Chugai) recently presented data from a phase I/II clinical study of their investigational bispecific antibody therapy NXT007, in people with hemophilia A who do not have factor VIII inhibitors. NXT007 is being…
Historically, women and girls affected by hemophilia have experienced protracted delays in securing an accurate diagnosis and care that takes bleeding disorders into full account. A newly published paper takes a 200+ year view of this history and…
Hemab Therapeutics recently presented clinical and preclinical stage data associated with two of their investigational therapies - Sutacimig (formerly HMB-001) and HMB-002. Hemab is a biotechnology company that specializes in the development of…